Sugi Predict

Sugi Predict / Compounds / SCHEMBL1991642

SCHEMBL1991642

SCHEMBL1991642

CC(C)(C)OC(=O)N1CCC(CO)C(F)C1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 1/20 0.49
▸ HPGD P15428 1/20 0.48
▸ RECQL P46063 1/20 0.46
▸ MAPT P10636 2/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ EPHX1 P07099 1/20 0.43
▸ DPP4 P27487 1/20 0.42
▸ USP2 O75604 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ GPR119 Q8TDV5 2/20 0.40
▸ JAK2 O60674 1/20 0.40
▸ JAK1 P23458 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ THRB P10828 1/20 0.39
▸ PTPN2 P17706 1/20 0.39
▸ PTPN1 P18031 1/20 0.39
▸ PTPN6 P29350 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15716049 1.00 NR1H2 (0.49) NR1H2HPGDRECQLMAPTMEN1
SCHEMBL15352745 1.00 NR1H2 (0.49) NR1H2HPGDRECQLMAPTMEN1
SCHEMBL15227164 1.00 NR1H2 (0.49) NR1H2HPGDRECQLMAPTMEN1
SCHEMBL15227465 1.00 NR1H2 (0.49) NR1H2HPGDRECQLMAPTMEN1
SCHEMBL27008159 0.89 HPGD (0.46) NR1H2HPGDRECQLMAPTMEN1
SCHEMBL15227941 0.89 HPGD (0.46) NR1H2HPGDRECQLMAPTMEN1
SCHEMBL26978402 0.89 HPGD (0.46) NR1H2HPGDRECQLMAPTMEN1
SCHEMBL29099052 0.89 HPGD (0.46) NR1H2HPGDRECQLMAPTMEN1
SCHEMBL15227944 0.89 HPGD (0.46) NR1H2HPGDRECQLMAPTMEN1
SCHEMBL27008212 0.89 HPGD (0.46) NR1H2HPGDRECQLMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4288426-B1 QUINOXALINE DERIVATIVES AND USES THEREOF BLACK DIAMOND THERAPEUTICS INC (US) 2026-02-04 — — EP disclosed
US-20250206745-A1 PYRROLOPYRIDAZINE DERIVATIVES AND RELATED USES NODTHERA LTD (GB) 2025-06-26 — — US disclosed
US-20240368181-A1 QUINOXALINE DERIVATIVES AND USES THEREOF BLACK DIAMOND THERAPEUTICS, INC. (US) 2024-11-07 — — US disclosed
US-12084445-B2 Broad-spectrum carbapenems VenatoRx Pharmaceuticals, Inc. (US) 2024-09-10 — — US disclosed
US-11958837-B2 Quinazolinones as PARP14 inhibitors RIBON THERAPEUTICS, INC. (US) 2024-04-16 — — US disclosed
EP-4288426-A1 QUINOXALINE DERIVATIVES AND USES THEREOF Black Diamond Therapeutics, Inc. (US) 2023-12-13 — — EP disclosed
CN-117203202-A Quinoxaline derivative and use thereof 黑钻治疗公司 2023-12-08 — — CN disclosed
WO-2023227125-A1 NEW FUSED-HETEROCYCLIC COMPOUND AS CDK INHIBITOR AND USE THEREOF 杭州德睿智药科技有限公司 2023-11-30 — — WO disclosed
WO-2023150525-A1 COMPETITIVE AND NONCOMPETITIVE PIPERIDINE SULFONYL INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 VANDERBILT UNIVERSITY (US) 2023-08-10 — — WO disclosed
EP-4212515-A1 QUINAZOLINONES AS PARP14 INHIBITORS Ribon Therapeutics Inc. (US) 2023-07-19 — — EP disclosed
WO-2016100349-A2 BICYCLIC AZAHETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS RUGEN HOLDINGS (CAYMAN) LIMITED (KY) 2016-06-23 — — WO disclosed
US-9242972-B2 Compounds GLAXO GROUP LIMITED (GB) 2016-01-26 — — US disclosed
US-9187435-B2 Bridged Spiro[2.4]heptane ester derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2015-11-17 — — US disclosed
EP-2640699-B1 BRIDGED SPIRO[2,4]HEPTANE ESTER DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2015-10-07 — — EP disclosed
US-20150065507-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2015-03-05 — — US disclosed
EP-2841430-A1 NOVEL COMPOUNDS Glaxo Group Limited (GB) 2015-03-04 — — EP disclosed
WO-2014078331-A1 N-(ARYLALKYL)-N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2014-05-22 — — WO disclosed
WO-2013160419-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2013-10-31 — — WO disclosed
US-20130231319-A1 Bridged Spiro[2.4]heptane Ester Derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2013-09-05 — — US disclosed
US-20110152243-A1 NOVEL THIENOPYRROLE COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11958837-B2 Quinazolinones as PARP14 inhibitors PARP14, PARP15, PARP11 NR1H2 3592/4885HPGD 658/4885RECQL 538/4885
US-20150065507-A1 NOVEL COMPOUNDS RORC, RORB, RORA NR1H2 7/4885HPGD 2325/4885RECQL 4290/4885
US-20110152243-A1 NOVEL THIENOPYRROLE COMPOUNDS TPMT, TSLP, THPO NR1H2 2172/4885HPGD 180/4885RECQL 3604/4885
US-20250206745-A1 PYRROLOPYRIDAZINE DERIVATIVES AND RELATED USES IL1B, NLRP3, NLRP1 NR1H2 3428/4885HPGD 115/4885RECQL 1041/4885
US-20240368181-A1 QUINOXALINE DERIVATIVES AND USES THEREOF NQO2, NQO1, GLS NR1H2 1901/4885HPGD 143/4885RECQL 14/4885
US-20130231319-A1 Bridged Spiro[2.4]heptane Ester Derivatives ADH1A, ADH1C, NAPA NR1H2 831/4885HPGD 2709/4885RECQL 4762/4885
US-12084445-B2 Broad-spectrum carbapenems MGAM, ALPI, SI NR1H2 2088/4885HPGD 1250/4885RECQL 1157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.